Antitumor effect of B16 melanoma cells genetically modified with the angiogenesis inhibitor RNasin

Cancer Gene Therapy

Volumn 8, Issue 4, 2001, Pages 278-284

  Botella Estrada, Rafael ^a,c   Malet, Gema ^b   Revert, Fernando ^b   Dasí, Francisco ^b   Crespo, Antonio ^b   Sanmartín, Onofre ^a   Guillén, Carlos ^a   Aliño, Salvador F ^b  

^a UNIVERSITY OF VALENCIA   (Spain)

^b UNIVERSITY OF VALENCIA   (Spain)

^c INSTITUTO VALENCIANO DE ONCOLOGÍA   (Spain)

Author keywords

Angiogenesis; Antiangiogenesis; Gene therapy; Melanoma; Ribonuclease inhibitor; RNasin

Indexed keywords

ANGIOGENESIS INHIBITOR; RIBONUCLEASE;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTERY DIAMETER; ARTICLE; DNA MODIFICATION; DRUG EFFECT; ENDOTHELIUM CELL; EXTRACELLULAR MATRIX; GENE THERAPY; GROWTH INHIBITION; MELANOMA CELL; MOLECULAR CLONING; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR GROWTH; VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANIMALS; CELL DIVISION; DNA PRIMERS; ENZYME INHIBITORS; GENE EXPRESSION; GENE THERAPY; GENETIC VECTORS; HUMANS; IMMUNOENZYME TECHNIQUES; LUNG NEOPLASMS; MELANOMA, EXPERIMENTAL; MICE; NEOVASCULARIZATION, PATHOLOGIC; PLACENTAL HORMONES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RIBONUCLEASES; RNA, MESSENGER; TRANSCRIPTION, GENETIC; TRANSFECTION; TUMOR CELLS, CULTURED;

ANIMALIA; MURINAE;

EID: 0035008898     PISSN: 09291903     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.cgt.7700302     Document Type: Article

References (27)

1. Folkman J, Hahnfeldt P, Hlatky L. The logic of antiangiogenic gene therapy. In: Friedmann T, ed. The Development of Human Gene Therapy. New York: Cold Spring Harbor Laboratory Press; 1999:527-543.
2. Boehm T, Folkman J, Bowden T, et al. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature. 1997;390:404-407.
3. Millauer B, Shawver LK, Plate KH, et al. Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant. Nature. 1994;367:576-579.
4. Lin P, Buxton JA, Acheson A, et al. Antiangiogenic gene therapy targeting the endothelium-specific receptor tyrosinase kinase Tie2. Proc Natl Acad Sci USA. 1998;95:8829-8834.
5. Goldman CK, Kendall RL, Cabrera G, et al. Paracrine expression of a native soluble vascular endothelial growth factor receptor inhibits tumor growth, metastasis, and mortality rate. Proc Natl Acad Sci USA. 1998;95:8795-8800.
6. Guo N, Krutzsch HC, Inman JK, et al. Thrombospondin 1 and type I repeat peptides of thrombospondin 1 specifically induce apoptosis of endothelial cells. Cancer Res. 1997;57:1735-1742.
7. Dhanabal M, Ramchandran R, Waterman MJ, et al. Endostatin induces endothelial cell apoptosis. J Biol Chem. 1999;274: 11721-11726.
8. Lucas R, Holmgren L, Garcia I, et al. Multiple forms of angiostatin induce apoptosis in endothelial cells. Blood. 1998; 92:4730-4741.
9. Polakowski IJ, Lewis MK, Muthukkaruppan VR, et al. A ribonuclease inhibitor expresses antiangiogenic properties and leads to reduced tumor growth in mice. Am J Pathol. 1993;143: 507-517.
10. Shapiro R, Vallee BL. Human placental ribonuclease inhibitor abolishes both angiogenic and ribonucleolytic activities of angiogenin. Proc Natl Acad Sci USA. 1987;84:2238-2241.
11. O'Reilly MS, Holmgren L, Shing Y, et al. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell. 1994;79:315-328.
12. O'Reilly MS, Boehm T, Shing Y, et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell. 1997;88:277-285.
13. Cao Y, O'Reilly MS, Marshall B, et al. Expression of angiostatin cDNA in a murine fibrosarcoma suppresses primary tumor growth and produces long-term dormancy of metastases. J Clin Invest. 1998;101:1055-1063.
14. Vlodavsky I, Korner G, Ishai-Michaeli P, et al. Extracellular matrix-resident growth factors and enzymes: possible involvement in rumor metastasis and angiogenesis. Cancer Metastasis Rev. 1990;9:203-226.
15. Weinstat-Saslow DL, Zabrenetzky VS, VanHoutte K, et al. Transfection of thrombospondin 1 complementary DNA into a human breast carcinoma cell line reduces primary tumor growth, metastatic potential, and angiogenesis. Cancer Res. 1994;54:6504-6511.
16. Hannahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell. 1996;86: 353-364.
17. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other diseases. Nat Med. 1995;1:27-31.
18. Fidler IJ, Ellis LM. The implications of angiogenesis for the biology and therapy of cancer metastasis. Cell. 1994;79:185-188.
19. Papageorgiou AC, Shapiro R, Acharya KR. Molecular recognition of human angiogenin by placental ribonuclease inhibitor - an X-ray crystallographic study at 2.0 Å resolution. EMBO J. 1997;16:5162-5177.
20. Fett JW, Strydom DJ, Lobb RR, et al. Isolation and characterization of angiogenin, an angiogenic protein from human carcinoma cells. Biochemistry. 1985;24:5480-5486.
21. Strydom DJ, Fett JW, Lobb RR, et al. Amino acid sequence of human tumor-derived angiogenin. Biochemistry. 1985;24: 5486-5494.
22. Kurachi K, Davie EW, Strydom DJ, et al. Sequence of the cDNA and gene for angiogenin, a human angiogenesis factor. Biochemistry. 1985;24:5494-5499.
23. Shapiro R, Weremowicz S, Riordan JF, et al. Ribonucleolytic activity of angiogenin: essential histidine, lysine, and arginine residues. Proc Natl Acad Sci USA. 1987;84:8783-8787.
24. Shapiro R, Fox EA, Riordan JF. Role of lysines in human angiogenin: chemical modification and site-directed mutagenesis. Biochemistry. 1989;28:1726-1732.
25. Shapiro R, Vallee BL. Site-directed mutagenesis of histidine-114 of human angiogenin. Alanine derivatives inhibit angiogenin-induced angiogenesis. Biochemistry. 1989;28:7401-7408.
26. Harper JW, Vallee BL. Mutagenesis of aspartic acid-116 enhances the ribonucleolytic activity and angiogenic potency of angiogenin. Proc Natl Acad Sci USA. 1988;85:7139-7143.
27. Hallahan TW, Shapiro R, Vallee BL. Dual-site model for the organogenic activity of angiogenin. Proc Natl Acad Sci USA. 1991;82:2222-2226.